Pan-Cefazolin Infusion
Cefazolin
1g
PANPHARMA
| Pack size | 25 Glass Vials |
|---|---|
| Dispensing mode | POM |
| Source | FRANCE |
| Agent | PHARMALINK |
| Retail Price | 148.50 AED |
Indications
Pan-Cefazolin Infusion is used for:
Infections With Gram-Positive Cocci, Mild-to-Moderate Cholecystitis, Uncomplicated Urinary Tract Infection, Prophylaxis against surgical infection, Endocarditis, Community-Acquired Pneumonia
Adult Dose
Parenteral
Susceptible infections
Adult: Mild: 0.25-0.5 g 8 hrly.
Moderate to severe: 0.5-1 g 6-8 hrly.
Severe, life-threatening: 1-1.5 g 6 hrly. Max: 12 g daily.
All doses to be given by deep IM inj, slow IV inj over 3-5 min, or intermittent or continuous IV infusion.
Mild Infections With Gram-Positive Cocci
250-500 mg IV q8hr
Mild-to-Moderate Cholecystitis
1-2 g IV q8hr for 4-7 days
Uncomplicated Urinary Tract Infection
1 g IV q12hr
Preparation for Surgery
Prophylaxis against infection
Preoperatively: 1-2 g IV/IM ?60 minutes before procedure (may be repeated in 2-5 hours intraoperatively)
Postoperatively: 0.5-1 g IV q6-8hr for 24 hours
Surgical infection
Cardiac procedures, hysterectomy, oral or pharyngeal procedures, craniotomy, joint replacement, thoracic procedures, arterial procedures, amputation, traumatic wounds; high-risk esophageal, gastroduodenal, or biliary tract procedures: 1-2 g IV
Colorectal procedures: 1-2 g IV plus metronidazole 0.5 g IV
High-risk cesarean section, 2nd trimester abortion: 1 g IV
Ophthalmic procedures: 100 mg subconjunctivally
Endocarditis
1 g IV/IM 30-60 minutes before procedure
American Heart Association (AHA) guidelines: Endocarditis prophylaxis recommended only for high-risk patients
Child Dose
Parenteral
Susceptible infections
Child: >1 yr 25-50 mg/kg daily in 3 or 4 divided doses to be given by deep IM inj, slow IV inj over 3-5 min, or intermittent or continuous IV infusion.
Max: 100 mg/kg daily in divided doses for severe infections.
Infections With Gram-Positive Cocci
Neonates (<28 days)
<7 days: 40 mg/kg/day IV/IM divided q12hr
>7 days, <2 kg: 40 mg/kg/day IV/IM divided q12hr
>7 days, >2 kg: 60 mg/kg/day IV/IM divided q8hr
Infants & children
25-100 mg/kg/day IV/IM divided q6-8hr; not to exceed 6 g/day
Endocarditis
Prophylaxis
50 mg/kg IV/IM ?30-60 minutes before procedure; not to exceed 1 g
AHA guidelines: Endocarditis prophylaxis recommended only for high-risk patients
Community-Acquired Pneumonia
>3 months and children: 150 mg/kg/day IV/IM divided q8hr (moderate to severe infections, methicillin susceptible S.Aureus preferred
Renal Dose
Renal impairment:
CrCl (ml/min) Dosage Recommendation
<10 Half the usual dose 18-24 hrly.
11-34 Half the usual dose 12 hrly.
35-54 Usual dose at intervals of at least 8 hr.
Administration
IV Preparation
Reconstitute 500 mg or 1 g with 2 mL or 2.5 mL SWI, respectively, to provide solutions containing approximately 225 or 330 mg/mL
IV push: Further dilute in approximately 5 mL of SWI or according to manufacturer's directions
Infusion: Dilute reconstituted 500 mg or 1 g solution in 50-100 mL NS or D5W
IM Preparation
Reconstitute 500 mg or 1 g with 2 mL or 2.5 mL SWI, respectively, to provide solutions containing approximately 225 or 330 mg/mL
IV Administration
IV push
Administer directly into vein, and infuse over 3-5 minutes or slowly into tubing of compatible IV infusion solution
IM Administration
Inject deep into large muscle mass
Contra Indications
Hypersensitivity to cephalosporins.
Precautions
Patient w/ history of hypersensitivity to penicillins, GI disease particularly colitis, seizure disorder. Renal impairment. Pregnancy and lactation. Monitoring Parameters Monitor prothrombin time; renal, hepatic and haematological function; monitor for signs of anaphylaxis during 1st dose.
Lactation: Drug excreted in breast milk; use with caution (American Academy of Pediatrics committee states that drug is compatible with nursing)
Pregnancy-Lactation
Pregnancy category: B
Lactation: Drug excreted in breast milk; use with caution (American Academy of Pediatrics committee states that drug is compatible with nursing)
Interactions
May enhance the anticoagulant effect of vit K antagonists (e.g. warfarin). May diminish the therapeutic effect of Na picosulfate, BCG and typhoid vaccine. May decrease the protein binding of fosphenytoin and phenytoin. Probenecid may decrease renal tubular secretion of cefazolin, resulting in increased and prolonged blood levels. May increase the nephrotoxic effects of aminoglycosides.
Adverse Effects
Side effects of Cefazolin :
Diarrhoea, oral candidiasis, vomiting, nausea, stomach cramps, anorexia; eosinophilia, itching, drug fever, skin rash, Stevens-Johnson syndrome; neutropenia, leucopenia, thrombocytopenia, thrombocythemia; transient elevation in SGOT, SGPT and alkaline phosphatase levels; hepatitis; increased BUN and creatinine levels, renal failure; phlebitis, induration; genital and anal pruritus (e.g. vulvar pruritus, genital moniliasis, vaginitis).
Potentially Fatal: Anaphylaxis, pseudomembranous colitis.
Mechanism of Action
Cefazolin binds to 1 or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
Note
Pan-Cefazolin 1g Infusion manufactured by PANPHARMA. Its generic name is Cefazolin. Pan-Cefazolin is availble in United Arab Emirates.
Farmaco UAE drug index information on Pan-Cefazolin Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.